Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
101 studies found for:    Obinutuzumab
Show Display Options
Rank Status Study
1 Not yet recruiting Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Biological: Obinutuzumab
2 Withdrawn Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)
Conditions: Post-transplant Lymphoproliferative Disorder;   PTLD
Intervention: Drug: Obinutuzumab
3 Completed
Has Results
An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Chlorambucil
4 Completed
Has Results
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Condition: Lymphocytic Leukemia, Chronic, Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Intervention: Drug: Obinutuzumab
5 Not yet recruiting Lenalidomide and Obinutuzumab for Previously Untreated CLL
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab
6 Active, not recruiting TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: TGR-1202 + Obinutuzumab + Chlorambucil
7 Recruiting Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Condition: Leukemia
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab
8 Active, not recruiting A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
Condition: Kidney Failure, Chronic
Interventions: Drug: Obinutuzumab;   Drug: Intravenous Immunoglobulin
9 Recruiting Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Lenalidomide
10 Recruiting Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: GA101;   Drug: ibrutinib
11 Recruiting Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Drug: obinutuzumab
12 Not yet recruiting Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome
Conditions: Richter's Syndrome;   CLL
Intervention: Drug: Obinutuzumab, lenalidomide, HDMP
13 Recruiting A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Ibrutinib
14 Not yet recruiting A Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
Condition: Graft vs. Host Disease
Interventions: Drug: Obinutuzumab;   Drug: Placebo
15 Not yet recruiting Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Condition: Relapsed or Refractory Follicular Lymphoma
Interventions: Drug: INCB050465;   Drug: Bendamustine;   Drug: Obinutuzumab
16 Recruiting Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Condition: Follicular Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Venetoclax
17 Active, not recruiting A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax (GDC-0199) Versus Obinutuzumab + Chlorambucil in Participants With Chronic Lymphocytic Leukemia
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: Chlorambucil;   Drug: Venetoclax;   Drug: Obinutuzumab
18 Recruiting A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
Condition: B-Cell Chronic Lymphocytic Leukemia
Interventions: Drug: Chlorambucil;   Drug: Obinutuzumab;   Drug: Placebo;   Other: Standard Premedication;   Drug: Tocilizumab
19 Recruiting A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Chlorambucil;   Drug: Obinutuzumab
20 Completed
Has Results
A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)
Condition: Lymphoma
Intervention: Drug: Obinutuzumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.